

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DKT NO.
B185 1210.1

SERIAL NO.
10/659,789

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICANT
Stenland, *et al.*

FILING DATE
09/10/03

GROUP
1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CL.	SUBCL.	FILING DATE IF APPROP.
MH	P1	US 2002/0192794 A1	12/19/02	Dadd, <i>et al.</i>	435	217	
	P2	6,437,102	08/20/02	Lee, <i>et al.</i>	530	412	
	P3	5,290,703	03/01/94	Hsu, <i>et al.</i>	436	71	
	P4	5,141,872	08/25/92	Tamir, I.	436	71	
	P5	5,085,784	02/04/92	Ostreicher, E.A.	210	767	
	P6	2,390,074	12/04/45	Cohn, E.J.	260	122	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CL.	SUBCL.	TRANSLATION
--	--	--------------	------	---------	-----	--------	-------------


OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)

MH	D1	Alpers, M.P., "Epidemiology and Ecology of Kuru," Vol. 1, pp. 67-90, in <i>Slow Transmissible Diseases of the Nervous System</i> , Academic Press, Inc., publisher, S. B. Prusiner and W. J. Hadlow, editors (1979).
	D2	Bolton, D.C., <i>et al.</i> , "Isolation and Structural Studies of the Intact Scrapie Agent Protein," <i>Arch. Biochem. Biophys.</i> , 258(2): 579-590 (1987).
	D3	Brown, P., <i>et al.</i> , "'Friendly Fire' in medicine: hormones, homografts, and Creutzfeldt-Jakob disease," <i>Lancet</i> , 340(8810): 24-27 (1992).
	D4	Brown, P., <i>et al.</i> , "The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy," <i>Transfusion</i> , 38(9): 810-816 (1998).
	D5	Chazot, G., <i>et al.</i> , "New Variant of Creutzfeldt-Jakob disease in a 26-year-old French man," <i>Lancet</i> , 347(9009): 1181 (1996).
	D6	Lee, D.C., <i>et al.</i> , "Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein," <i>J. Virol. Methods</i> , 84: 77-89 (2000).
	D7	Lee, D.C., <i>et al.</i> , "A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins," <i>Transfusion</i> , 41(4): 449-455 (2001).
	D8	Prusiner, S.B., "Molecular Biology of Prion Diseases," <i>Science</i> , 252: 1515-1522 (1991).
	D9	Stenland, C.J., <i>et al.</i> , "Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma," <i>Transfusion</i> , 42(11): 1497-1500 (2002).
	D10	Will, R.G., <i>et al.</i> , "A new variant of Creutzfeldt-Jakob Disease in the UK," <i>Lancet</i> , 347(9006): 921-925 (1996).

EXAMINER /Michelle Horning/

DATE CONSIDERED 07/27/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/659,789
Filing Date	09/10/03
First Named Inventor	Stenland, et al.
Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	B185 1210.1

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials ^a	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ^d
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
↓	F1	WO 97/45746	12/04/97	McGill Univ.		
	F2	WO 01/00235	01/04/01	McGill Univ.		
	F3	WO 02/090379	11/14/02	Serologicals		

**Examiner
Signature**

/Michelle Horning/

Date
Considered

07/27/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number		10/659,789
				Filing Date		September 10, 2003
				First Named Inventor		Stenland, et al.
				Art Unit		1645
Examiner Name		Unassigned				
Sheet	2	of	2	Attorney Docket Number		B185 1210.1 (MSC 8015)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.	T ²
MH	D1	Pan, K.M., et al., "Purification and Properties of the Cellular Prion Protein from Syrian Hamster Brain," <i>Protein Science</i> , 1: 1343-1352 (1992).	
MH	D2	Van Holten, R.W., et al., "Removal of prion challenge from an immune globulin preparation by use of a size-exclusion filter," <i>Transfusion</i> , 52: 999-1004 (2002).	
MH	D3	INTERNATIONAL SEARCH REPORT (PTC/US2004/029024, dated 26 November 2004).	

Examiner Signature	/Michelle Horning/	Date Considered	07/27/2006
-----------------------	--------------------	--------------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select optio